Stroke is the third most common cause of disability worldwide and leads to upper limb motor disease in more than half of people affected. Recent data demonstrate that upper limb rehabilitation can be pursued using techniques such as the observation of action (Action Observation Therapy - AOT) or the stimulation of limb musculature using surface electrodes (Neuromuscular Electrical Stimulation - NMES). To date, no rehabilitation studies used both the treatments (AOT-NMES) for the rehabilitation of upper limb after stroke. The goal of this clinical trial is to study the efficacy of this combined approach (AOT-NMES) in people who developed upper limb motor impairment after stroke. The main question this study aims to answer is if the rehabilitation performed using both action observation and neuromuscular stimulation has an higher efficacy than the use of AOT alone and higher than the observation of non-motor stimuli. Participants will be people with upper limb impairment after stroke and will perform 15 rehabilitation sessions (5/week, 3 weeks, 60 minutes each). Each participant will be casually included in one of following three rehabilitation groups: * Action observation associated with neuromuscular stimulation (AOT-NMES, experimental condition): they will observe upper limb movements while their arm muscles will be stimulated. After the observation phase they will try to perform the same movements with the impaired arm. * Action observation alone (AOT): subjects will observe upper limb movements and after the observation phase then they will try to execute them with the impaired arm. * Motor-neutral observation (MNO): subjects will observe non-movement videos and after the observation phase they will try to execute upper limb movements with the impaired arm. Each participant will be evaluated for motor function before and after rehabilitation treatment and researchers will compare the motion improvement between the groups to assess the efficacy of AOT-NMES over other treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
Action observation and neuromuscular electrical stimulation followed by motor execution
Action observation followed by motor execution
Motor-neutral observation followed by motor execution
IRCCS Fondazione Don Carlo Gnocchi
Milan, Italia, Italy
RECRUITINGChanges in measure of upper extremity motor performance as assessed using the Fugl-Meyer Assessment of Motor Recovery after Stroke - Upper Extremity (FMA-UE) score.
The Fugl-Meyer Assessment of Motor Recovery after Stroke is one of the most widely used measures of motor impairment in post-stroke hemiplegic patients, covering 5 domains (Motor function, sensory function, balance, joint range of motion, joint pain). The assessment of upper extremity motion is performed using the Upper Extremity assessment (FMA-UE), including items scored on a 3-point ordinal scale (0: cannot perform, 1: performs partially; 2: performs fully) with total maximum score: 66 points (higher scores, best clinical profile).
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in measure of upper limb functioning as assessed using the Action Research Arm test (ARAT)
The ARAT test assess upper limb functioning through the execution of 19 tasks, divided in 4 sub-tests (grasp, grip, pinch, and gross arm movement). Each movement is scored on a 4-point ordinal scale (0=no movement, 1=movement partially performed, 2=movement completed but takes abnormally long; 3=movement performed normally). Total possible score is 57 points, with higher scores associated to best motor functioning.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in health and disability status as measured using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
WHODAS 2.0 is an instrument assessing the level of health and disability across all diseases, directly linked to the concepts of the International Classification of Functioning, Disability and Health (ICF). WHODAS 2.0 covers 6 domains (Cognition, Mobility, Self-care, Getting along, Life activities, Participation) and scores range for each item from 0 to 4 (higher scores, higher disability). The 36-items version will be administered. Summary score (possible total score: 144) and domain-specific scores (score 0-24 for each domain) will be considered as outcome measures.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in Stroke-associated quality of life as assessed using specific subscores of the Stroke Impact Scale (SIS) 3.0
The Stroke Impact Scale 3.0 specifically measures quality of life in stroke survivors, considering multiple dimensions (strength, hand function, mobility, activities of daily living (ADL)/instrumental activities of daily living (IADL), memory, communication, emotion, social participation). Each of the 59 items can be rated on a 5-point Likert scale (from 1 to 5), with higher values corresponding to better quality of life. Each subscale of the SIS 3.0 may have a score from 0 to 100.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in quality of life as self-rated in the EuroQol five dimensions (5D) and five levels (5L) questionnaire (EQ-5D-5L)
The EQ-5D-5L is an instrument measuring health status, yet applied in different populations and settings. The EQ-5D-5L considers five dimensions (5D: mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of them measured with a single item scored on 5 levels (5L: no problems, slight problems, moderate problems, severe problems and extreme problems). The selected level for each dimension is represented by a single digit (from 1: no problems to 5: extreme problems) and the digits of the five levels are combined in a 5-digits number describing the patient's health state, raging from 11111 (no problems in all dimensions) to 5555 (extreme problems in all dimensions).
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in global cognitive functioning as assessed using the Montreal COgnitive Assessment (MoCA) score.
The MoCA test is a screening tool assessing global cognitive functioning across eight domains (orientation, visuospatial abilities, executive function, naming, memory, attention, language, abstraction). The possible maximun total score is 30, with higher values indicating a more preserved cognitive functioning.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in muscular electrical activity during motor acts as measured using surface Electromyography (EMGs).
Surface Electromyography (EMGs) is a non-invasive tool able to assess muscular electrical activity during the execution of active movements using electrodes applied on the skin surface. Muscular contraction amplitude will be recorded from 24 sensors placed on upper limbs (12 sensors/limb), during the execution of motor acts. Then, the difference between patient's and observed model's temporal dynamic of muscular contraction will be chosen as EMG outcome.
Time frame: Baseline, 1 month (End of treatment)
Changes in the corticospinal excitability, assessed using Motor Evoked Potentials (MEPs).
Motor evoked potentials (MEPs) can indicate the level of corticospinal excitability and the integrity of motor pathways. Motor potentials in first digital interosseus muscle will be evoked via Transcranial Magnetic Stimulation (TMS, single pulse) and peak-to-peak amplitudes will be recorded as indices of cortico-spinal excitability (i.e. integrity of motor pathways).
Time frame: Baseline, 1 month (End of treatment)
Changes in motoneuron reflex excitability measured as H/M ratio amplitude.
The H/M ratio is an index of motorneuron reflex excitability. The H/M ratio amplitude will be recorded over the Flexor Carpi Radialis muscle, evoked through the stimulation of the median nerve and eliciting H-reflex in extensor carpi radialis longus (ECRL) and flexor carpi radialis (FCR)
Time frame: Baseline, 1 month (End of treatment)
Changes in movement parameters extracted from body kinematics.
Kinematics of the upper limb and trunk will be recorded using a 9 camera optoelectronic system during 3D motor acts. The system will measure the 3D coordinates of spherical markers attached to body landmarks to compute trunk, shoulder, elbow and wrist angles. Data processing will provide measures of deviations from physiological movement.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in muscular synergies
Muscle synergies will be extracted from the EMG envelope of each subject using the Non Negative Matrix Factorization algorithm. Short- and long-term changes induced by treatment in the similarities of muscle synergies with respect to physiological pattern will be evaluated. The module similarity will be measured by the maximum scalar product of the muscle weightings of each module between each participant and the normative reference, while the activation profile similarity by the Pearson's correlation coefficient of the activation profile of each module.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in microstructural brain properties, assessed using advanced Magnetic Resonance Imaging (MRI) techniques.
High-resolution structural sequences will be collected using Magnetic Resonance Imaging at 3.0 Tesla. Data on gray matter will be acquired using MPRAGE (T1w MPRAGE, at least 1x1x1 mm resolution) and FLAIR (1x1x1 mm resolution) sequences. White matter microstructure images will be collected using a DWI protocol (2x2x2 mm resolution, 5 b0 images, 50 directions). Data processing will provide measures of brain integrity, with higher integrity corresponding to more preserved brains.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
Changes in brain sensory-motor networks, as investigated using functional Magnetic Resonance Imaging (fMRI).
Sensory-motor brain networks will be assessed using advanced functional Magnetic Resonance Imaging (fMRI) protocols. Data will be acquired on a 3.0T scanner and will provide insights about spared/recovered neural correlates of sensory-motor function.
Time frame: Baseline, 1 month (End of treatment), 6 months (Follow-up)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.